Advances on Etiology of Uterine Leiomyosarcoma

YAN Hao; YANG Runfeng; LIU Li

doi:10.3971/j.issn.1000-8578.2015.10.022

Cancer Research on Prevention and Treatment > 2015 > 42(10): 1054-1058. > DOI: 10.3971/j.issn.1000-8578.2015.10.022

YAN Hao, YANG Runfeng, LIU Li. Advances on Etiology of Uterine Leiomyosarcoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(10): 1054-1058. DOI: 10.3971/j.issn.1000-8578.2015.10.022

Citation:

YAN Hao, YANG Runfeng, LIU Li. Advances on Etiology of Uterine Leiomyosarcoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(10): 1054-1058. DOI: 10.3971/j.issn.1000-8578.2015.10.022

Citation:

YAN Hao, YANG Runfeng, LIU Li. Advances on Etiology of Uterine Leiomyosarcoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(10): 1054-1058. DOI: 10.3971/j.issn.1000-8578.2015.10.022

PDF (1499 KB)

Advances on Etiology of Uterine Leiomyosarcoma

Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan 430079, China

More Information

Received Date: February 11, 2015
Revised Date: April 14, 2015

Graphical Abstract

Abstract

Abstract

Uterine leiomyosarcoma(ULMS) is an aggressive, rapidly progressive uterine malignancy lacking specific biomarkers of clinic screening, resulting in an extremely low preoperative diagnostic rate. The treatment of this malignant tumor is primarily surgery, supplemented by radiotherapy, chemotherapy, targeted therapy, hormonotherapy and biotherapy; however, there is no obvious curative effect. Recently, great advancement has been achieved in searching biomarkers related to the diagnosis and prognosis of ULMS from etiology. This review will investigate the etiology and mechanism of ULMS from the perspective of epidemiological studies, hormone, gene and molecular biomarkers, in order to provide new ideas for clinical diagnosis and treatment.
- Uterine leiomyosarcoma(ULMS),
- Etiology,
- Pathogenesis

FullText(HTML)

References (40)

References

[1]	Felix AS, Cook LS, Gaudet MM, et al. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium[J]. Br J Cancer, 2013, 108(3): 727-34.
[2]	Rauh-Hain JA, Hinchcliff EM, Oduyebo T, et al. Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma[J]. Int J Gynecol Cancer, 2014, 24(8): 1434-40.
[3]	Smith T, McLaughlin P. Uterine leiomyosarcoma: diagnosis, treatment, and nursing management[J]. Clin J Oncol Nurs, 2012, 16 (3): 267-72.
[4]	Lin JF, Slomovitz BM.Uterine sarcoma 2008[J]. Curr Oncol Rep, 20 08, 10(6): 512-8.
[5]	Hewedi IH, Radwan NA, Shash LS. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors[J]. Diagn Pathol, 2012, 7: 1.
[6]	Petrovi? D, Babi? D, Forko JI, et al. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. diagnostic value[J]. Coll Antropol, 2010, 34(1): 93-7.
[7]	L e i t a o MM J r , He n s l e y ML , Ba r a k a t RR, e t a l . Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma[J]. Gynecol Oncol, 2012, 124(3): 558-62.
[8]	Koivisto-Korander R, Leminen A, Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma[J]. Obstet Gynecol, 2007, 109(2 pt2): 512-4.
[9]	Dizon DS, Birrer MJ. Advances in the diagnosis and treatment of uterine sarcomas[J]. Discov Med, 2014, 17(96): 339-45.
[10]	LoizziV, Cormio G, Nestola D, et al. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma[J]. Oncology, 20 11, 81(2): 91-7.
[11]	Wang HX, Qu LH, Wang YK, et al. Expression of ERα, ERβ, pS2 in uterineleiomyosarcoma[J]. Zhonguo You Sheng Yu Yi Chuan Za Zhi, 2006, 4(14): 32-4. [ ϼ, , Կ . ERα ERβ pS2 ӹ ƽ ֯ еı Ｐ [J]. Ŵ ־, 2006, 4(14): 32-4.]
[12]	Matsuda M, Ichimura T, Kasai M, et al. Preoperative diagnosis of usual leiomyoma, atypical leiomyoma, and leiomyosarcoma[J]. Sarcoma, 2014, 2014: 498682.
[13]	O’Neill CJ, McBride HA, Connolly LE, et al. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential[J]. Histopathology, 2007, 50(7): 851-8.
[14]	ChenL, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors[J]. Int J Gynecol Pathol, 2008, 27(3): 326-32.
[15]	D’Angelo E, Espinosa I, Ali R, et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis[J]. Gynecol Oncol, 20 11, 121(2): 328-33.
[16]	Naaman Y, Shveiky D, Ben-Shachar I, et al. Uterine sarcoma: prognostic factors and treatment evaluation[J]. Isr Med Assoc J, 20 11, 13(2): 76-9.
[17]	Anderson SE, Nonaka D, Chuai S, et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas[J]. Int J Gynecol Cancer, 2006, 16 (2): 849-53.
[18]	Gadducci A. Prognostic factors in uterine sarcoma[J]. Best Pract Res Clin Obstet Gynaecol, 2011, 25(6): 783-95.
[19]	Bodner-Adler B, Bodner K, Czerwenka K, et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis[J]. Gynecol Oncol, 2005, 96(1): 62-6.
[20]	Hakverdi S, Güngören A, Yaldiz M, et al. Immunohistochemical analysis of p16 expression in uterine smooth muscle tumors[J]. Eur J Gynaecol Oncol, 2011, 32(5): 513-5.
[21]	LusbyK, Savannah KB, Demi c co EG, e t al . Ut e r ine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution’s experience[J]. Ann Surg Oncol, 20 13, 20(7): 2364-72.
[22]	Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas[J]. Int J Gynecol Pathol, 1999, 18(1): 20-8.
[23]	Leiser AL, Anderson SE, Nonaka D, et al. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma[J]. Gynecol Oncol, 2006, 101(1): 86-91.
[24]	McGuireMM, Yatsenko A, Hoffner L, et al. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas[J]. PLoS One, 2012, 7(3): e33251.
[25]	Pérot G, Croce S, Ribeiro A, et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors[J]. PLoS One, 2012, 7(6): e40015.
[26]	Je EM, Kim MR, Min KO, et al. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors[J]. Int J Cancer, 2012, 131(6): E1044-7.
[27]	Schwetye KE, Pfeifer JD, Duncavage EJ. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors[J]. Hum Pathol, 20 14, 45(1): 65-70.
[28]	Bertsch E, Qiang W, Zhang Q, et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma[J]. Mod Pathol, 2014, 27(8): 1144-53.
[29]	Ravegnini G, Mariño-Enriquez A, Slater J, et al. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma[J]. Mod Pathol, 2013, 26(5): 743-49.
[30]	Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets[J]. Cell, 2005, 120(1): 15-20.
[31]	Cheng G. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy[J]. Adv Drug Deliv Rev, 2015, 81: 75-93.
[32]	Hayes J, Peruzzi PP, Lawler S, et al. MicroRNAs in cancer: biomarkers, functions and therapy[J]. Trends Mol Med, 2014, 20 (8): 460-9.
[33]	Shi G, Perle MA, Mittal K, et al. Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma[J]. J Cell Mol Med, 2009, 13(9B): 3898-905.
[34]	Zhang Q, Ubago J, Li L, et al. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma[J]. Cancer, 2014, 120(20): 3165-77.
[35]	Pan Q, Luo X, Chegini N. MicroRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells[J]. Mol Hum Reprod, 2010, 16 (3): 215-27.
[36]	Yu J, Sun SS, Zhang HF, et al. Clinical significance and expression of microRNA29 in uter leiomyosarcoma[J]. Shandong Yi Yao, 20 12, 52(24): 90-1. [ ھ , ˫˫, ź , . MicroRNA29 ӹ еı Ｐ ٴ [J]. ɽ ҽҩ, 2012, 52 (24): 90-1.]
[37]	Ozler A, Evsen MS, Turgut A, et al. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma[J]. J Exp Ther Oncol, 2014, 10(4): 325-30.
[38]	Hayashi T, Horiuchi A, Samo K, et al. Potential role of LMP2 as an anti-oncogenic factor in human uterine leiomyosarcoma: morpholoyical significance of calponin h1[J]. FEBS Lett, 2012, 58 6(13): 1824-31.
[39]	Hayashi T, Horiuchi A, Sano K, et al. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma[J]. Tumori, 2014, 100(4): 99e-106e.
[40]	Hayashi T, Horiuchi A, Sano K, et al. Involvement of proteasome β1i subunit, LMP2, on development of uterin leiomyosarcma[J]. N Am J Med Sci, 2011, 3(9): 394-9.

[1]	LAI Jing, LIN Peixin, HUANG Jing. Research Progress of Radiation-induced Brain Injury for Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1133-1138. DOI: 10.3971/j.issn.1000-8578.2023.23.0484
[2]	TIAN Daofa. Influence of Changing Tendency in Sense of Head and Neck Carcinogenesis on Current Therapeutic Ideas and Its Clinical Implications[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 769-773. DOI: 10.3971/j.issn.1000-8578.2022.21.1428
[3]	LU Wei, XIAO Qian, HU Yeting, KONG Xiangxing, DING Kefeng. Correlation of Pathogenesis, Early Diagnosis and Treatment of Colorectal Cancer with Microorganisms[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 909-914. DOI: 10.3971/j.issn.1000-8578.2020.20.0596
[4]	ZHAO Cuicui, LIU Hong. Molecular Biological Pathogenesis of Young Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(3): 213-217. DOI: 10.3971/j.issn.1000-8578.2020.19.1130
[5]	JIN Weihua, ZHANG Ruitao. Progress of Whole Exon Sequencing in Pathogenesis and Diagnosis of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(5): 482-485. DOI: 10.3971/j.issn.1000-8578.2019.18.1394
[6]	FU Danli, CHEN Peifeng. Pathogenesis of Malignant Tumor with Hypercoagulable State in Traditional Chinese Medicine and Western Medicine[J]. Cancer Research on Prevention and Treatment, 2018, 45(3): 179-182. DOI: 10.3971/j.issn.1000-8578.2018.17.0998
[7]	ZHANG Zongfeng, DU Juan. Relationship Between Human Papillomavirus and miRNA Expression[J]. Cancer Research on Prevention and Treatment, 2015, 42(11): 1152-1155. DOI: 10.3971/j.issn.1000-8578.2015.11.021
[8]	JIA Zhifeng, ZHENG Lihua, ZHAO Yaheng, FENG Jiangang. Advances in Pathogenesis of Synovial Sarcoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(07): 716-719. DOI: 10.3971/j.issn.1000-8578.2015.07.016
[9]	ZHAO Yaheng, FENG Helin, ZHENG Lihua, JIA Zhifeng, FENG Jiangang. Progress on Osteosarcoma Pathogenesis[J]. Cancer Research on Prevention and Treatment, 2014, 41(03): 283-286. DOI: 10.3971/j.issn.1000-8578.2014.03.019
[10]	FAN Rui-fang, LI Wen-hui, GU Shu-nan. Analysis of Pathogenesis,Prevention and Treatment of Implantation Metastases of Abdominal Wall[J]. Cancer Research on Prevention and Treatment, 2000, 27(01): 55-56. DOI: 10.3971/j.issn.1000-8578.2025

Cited By

Get Citation

PDF

XML

Article views (1364) PDF downloads (2099)

Turn off MathJax

Article Contents

Abstract

References

Advances on Etiology of Uterine Leiomyosarcoma

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Advances on Etiology of Uterine Leiomyosarcoma

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content